Lido Advisors’s Protalix BioTherapeutics PLX Stock Holding History

Lido Advisors’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$36.3K	Buy	15,560 +6	+0%	+$13	﹤0.01%	2095
2026 Q1	$33.8K	Hold	15,554	–	–	﹤0.01%	1913
2025 Q4	$34.5K	Hold	15,554	–	–	﹤0.01%	1896
2025 Q3	$34.5K	Hold	15,554	–	–	﹤0.01%	1805
2025 Q2	$23K	Hold	15,554	–	–	﹤0.01%	1633
2025 Q1	$39.8K	Hold	15,554	–	–	﹤0.01%	1481
2024 Q4	$29.2K	Hold	15,554	–	–	﹤0.01%	1476
2024 Q3	$15.9K	Hold	15,554	–	–	﹤0.01%	1450
2024 Q2	$18.2K	Hold	15,554	–	–	﹤0.01%	1400
2024 Q1	$19.6K	Hold	15,554	–	–	﹤0.01%	1370
2023 Q4	$27.7K	Sell	15,554 -300	-2%	-$467	﹤0.01%	1329
2023 Q3	$26.3K	Buy	15,854 +300	+2%	+$538	﹤0.01%	1189
2023 Q2	$31.1K	Hold	15,554	–	–	﹤0.01%	1193
2023 Q1	$32.7K	Buy	+15,554	New	+$27.3K	﹤0.01%	1129
2019 Q4	–	Sell	-1,600	Closed	-$3K	–	671
2019 Q3	$3K	Sell	1,600 -114	-7%	-$340	﹤0.01%	574
2019 Q2	$8K	Buy	+1,714	New	+$7.24K	﹤0.01%	536

Other funds holding PLX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Lido Advisors's PLX Position: Q2 2026 in Review

Lido Advisors increased its Protalix BioTherapeutics (PLX) stake by 0.04% in Q2 2026, buying an estimated $13 and bringing the position to 15,560 shares worth $36.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2095.

Lido Advisors first reported a position in PLX in Q2 2019 and has held it in 16 quarters since. The position peaked at $39.8K in Q1 2025. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

Lido Advisors held 15,560 shares of Protalix BioTherapeutics worth $36.3K as of Q2 2026.
Lido Advisors bought 6 Protalix BioTherapeutics shares in Q2 2026, an estimated $13.
Protalix BioTherapeutics made up ﹤0.01% of Lido Advisors's portfolio in Q2 2026, its #2095 holding.
Lido Advisors first reported a position in Protalix BioTherapeutics in Q2 2019 and has held it in 16 quarters since.
Lido Advisors's Protalix BioTherapeutics position peaked at $39.8K in Q1 2025.
102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Lido Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.